DeepLife is a techbio company advancing drug positioning through artificial intelligence and digital twins of human cell types.

Its platform, TwinCell, simulates cell-type-specific behaviour by integrating over 1 billion harmonized single-cell omics data points with causal AI, enabling more precise target identification, drug repositioning and disease understanding.

DeepLife applies this technology across autoimmune, neurodegenerative and cardio metabolic diseases among others. It partners with pharmaceutical and biotech companies on asset de-risking, indication expansion and disease relevant assessment. The company has established strategic collaborations including with Biersdorf in skin disease and aging.

DeepLife leverages cell-type-specific digital twin models to pinpoint the most relevant disease indications for any therapeutic compound. At the core is TwinCell – a large-scale causal model of cell biology that identifies the molecular drivers of disease and how to reverse them. TwinCell combines this insight with large scale single cell multi omics data to build precise models of human cell types and their regulatory networks.

These digital twins replicate real cellular behaviour, predicting preclinical outcomes and enabling researchers to explore disease mechanisms in silico. This approach uncovers how compounds act at the cell-type level, enhancing target validation, biomarker discovery and indication selection.

Applied across the drug development lifecycle, TwinCell accelerates decision making, reduces risk and improves translational relevance. It supports novel target discovery, asset de-risking, indication expansion and pipeline prioritization through strategic collaborations with pharmaceutical and biotech partners.